Perrigo receives final FDA approval for generic version of Valeant’s BenzaClin Pump Topical Gel

Shipments to customers have already commenced.

BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending February 2016 were $79 million.

Perrigo CEO John Hendrickson said: "This Rx product approval and launch demonstrates the team’s ability to leverage Perrigo’s manufacturing expertise in order to provide our customers with the latest technologies.

Providing our customers with convenient, cost effective technologies like the BenzaClin Pump furthers Perrigo’s commitment of delivering Quality Affordable Healthcare Products around the world."